GLOBUS MEDICAL INC (GMED) Form 8-K — Aug 6, 2026
Globus Medical (NYSE: GMED) reported second quarter 2026 net sales of $789.6 million, up 5.9% year over year (5.6% constant currency), with GAAP net income of $151.6 million and GAAP diluted EPS of $1.10. Non-GAAP diluted EPS was $1.34, up 55.8% from $0.86 in the prior-year quarter. The GAAP decline reflects the $110.5 million bargain purchase gain recognized in Q2 2025 on the Nevro acquisition rather than operational weakness. Adjusted gross margin expanded 200 basis points to 69.4% and Adjusted EBITDA rose to $279.8 million (35.4% of sales), driving record second quarter non-GAAP net income and EPS on the fifth straight quarter of above-market growth.
Key figures
- Eps
- 1.1
- Revenue
- 789612000
- Guidance
- FY2026 revenue reaffirmed at $3.18B-$3.22B; non-GAAP diluted EPS raised to $4.95-$5.05 from prior $4.70-$4.80
- Net Income
- 151569000
- Revenue Yoy
- 5.9% reported; 5.6% constant currency
- Total Assets
- 5488258000
- Cash Position
- 507745000
- Shares Outstanding
- 111,822,190 Class A + 22,430,097 Class B as of June 30, 2026
- Us Growth
- 3.0%
- H1 Net Sales
- 1549466000
- Us Net Sales
- 619105000
- Free Cash Flow H1
- 339322000
- Free Cash Flow Q2
- 176574000
- Gaap Eps Prior Year
- 1.49
- Non Gaa PEps Growth
- +55.8% vs $0.86 prior year
- Adjusted EBITDA Q2
- 279839000
- H1 Share Repurchases
- 136058000
- Adjusted Gross Margin
- 69.4%, up 200bps YoY
- Gaap Net Income Change
- -25.3% YoY
- International Growth
- 18.0% reported; 16.2% constant currency
- Adjusted EBITDAMargin
- 35.4% vs 28.0% prior year
- Non Gaa PDiluted EPS H1
- 2.46
- Non Gaa PDiluted EPS Q2
- 1.34
- Revenue Growth Ex Nevro
- 9%
- International Net Sales
- 170507000
- Prior Year Bargain Purchase Gain
- 110561000
- Total Cash And Marketable Securities
- 840500000
Price after filing
Close on the filing date to close N calendar days later (from $81.51). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.